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Available online 9 September 2015Understanding the etiology of cognitive deﬁcits in genetic disorders
holds great promise for advancing disease-speciﬁc treatments. The
availability of animal models has allowed detailed examination of
molecular pathways underlying the cognitive phenotype in numerous
Mendelian disorders, increasing optimism for mechanism-based treat-
ments. One such disorder is neuroﬁbromatosis type 1 (NF1), an autoso-
mal dominant condition associated with high rates of neurocognitive
deﬁcits, academic failure, attention deﬁcit hyperactivity disorder, psy-
chosocial maladjustment and motor coordination problems (Champion
et al., 2014; Payne et al., 2013). Mutations in the NF1 gene result in de-
creased levels of neuroﬁbromin; a negative regulator of the RAS signaling
cascade. Ensuing RAS hyperactivation increases activity-dependent
GABAergic neurotransmission and reduces synaptic plasticity, resulting
in behavioral impairment (Shilyansky et al., 2010). Preclinical trials
demonstrate that genetic and pharmacological interventions inhibiting
RAS transforming activity can rescue these cellular abnormalities and re-
verse themurine behavioral phenotype, providing a rationale for human
clinical trials (Li et al., 2005).
Despite signiﬁcant promise, early attempts at translating these pre-
clinicalﬁndings in randomized controlled trials have unfortunately failed
(Krab et al., 2008; van der Vaart et al., 2013). Translation of ﬁndings from
bench to clinically relevant therapies is notoriously complex, and treat-
ments for cognitive deﬁcits in patients with NF1 appear to be no differ-
ent. There are many reasons for this including lack of evidence for the
appropriate treatment dose to inhibit RAS activity in the brain and,
more importantly, minimal validation of the preclinical disease model
in the human disease state. The relative contributions of aberrant RAS
signaling, altered GABAergic neurotransmission and deﬁcient synaptic
plasticity to the NF1 cognitive phenotype in humans is also unknown.om.2015.08.036.
. This is an open access article underA new study by Zimerman and colleagues in this issue of
EBioMedicine is one of the ﬁrst to attempt to conﬁrm animal-
generated hypotheses in human patients and is of signiﬁcant
interest to NF1 cognitive research (Zimerman et al., 2015). The au-
thors examined the relationship between inhibitory GABAergic
neurotransmission and motor skill learning in a highly selected
sample of NF1 adults with normal cognitive and functional abilities.
Compared to matched controls, the NF1 group demonstrated
deﬁcient learning of a ﬁne motor task over a ﬁve day period, with
impairments driven by poorer initial learning (fast online) and
reduced ofﬂine consolidation of learned skills between training ses-
sions. This was accompanied by a double-pulse transcranial mag-
netic stimulation (TMS) experiment assessing short intracortical
inhibition (SICI) during performance of a reaction time task as
used previously (Heise et al., 2010; Hummel et al., 2009). In control
participants, reduced inhibition was reported at the end of the reac-
tion time period (i.e. just before movement onset) compared to
levels measured at the beginning of the reaction time period (i.e.
beginning of movement preparation). In contrast, this task-related
modulation of SICI was not observed in patients with NF1, with
trends towards increased inhibitory processes. Interestingly, the
authors report signiﬁcant correlations between behavioral im-
provements and the degree of SICI modulation, with a relative in-
crease in intracortical inhibition associated with reduced levels of
skill acquisition for NF1 patients. Interpreted within the context of
the animal literature, these ﬁndings provide an important step in
bridging the gap between animal models and the human condition,
suggesting dysfunctional GABAergic neurotransmission contributes
to procedural learning in patients with NF1. Results from a recent
magnetic resonance spectroscopy study, however, suggests the
relationship between GABA levels and the human phenotype is
more complex (Ribeiro et al., 2015). Lower levels of prefrontal
GABA were identiﬁed in children with NF1, which was
signiﬁcantly associated with poorer IQ, but also with better inhibi-
tory control. These data support the notion that abnormal inhibito-
ry neurotransmission contributes to the cognitive phenotype in
NF1, however together with the present data by Zimerman et al.,
they also indicate a more complex relationship between abnormal
GABA-ergic neurotransmission and cognitive functions. There
might not be a unitary inﬂuence of GABA-ergic dysfunction on all
cognitive domains with the same impact, but with differingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1291J.M. Payne / EBioMedicine 2 (2015) 1290–1291relevance depending on factors, such as age, cognitive function or
cortical area. Limitations of the Zimerman et al. study include
small sample sizes and a highly selected NF1 group controlled for
confounding factors that does not represent the broader NF1 popu-
lation, limiting conclusions that can be drawn.
While these studies have initiated an evidence base for the patho-
physiologic correlates of NF1 in the complex human condition, signiﬁcant
work validating meaningful cognitive biomarkers is still required.
Identifying cognitive biomarkers, speciﬁcally and directly regulated by
neuroﬁbromin, would enable smaller pilot studies to demonstrate proof
of principle anddose reﬁnement by testingwhether promisingpreclinical
treatments normalize pathophysiologic processes in human patients
before expensive randomized controlled trials are conducted. Such an ap-
proach would result in better informed clinical research, optimizing trial
designs based on ﬁndings observed in humans.Conﬂict of Interest
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